

CITATION REPORT

List of articles citing

**HBV genotypes: relevance to natural history,
pathogenesis and treatment of chronic hepatitis B**

DOI: 10.3851/imp1982
Antiviral Therapy, 2011, 16, 1169-86.

Source: <https://exaly.com/paper-pdf/50889152/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
140	Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. 2012 , 12, 307		30
139	Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. <i>PLoS ONE</i> , 2012 , 7, e39028	3.7	33
138	Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. <i>PLoS ONE</i> , 2012 , 7, e50787	3.7	21
137	Hepatitis B precore protein: pathogenic potential and therapeutic promise. 2012 , 53, 875-85		23
136	African, Amerindian and European hepatitis B virus strains circulate on the Caribbean Island of Martinique. <i>Journal of General Virology</i> , 2013 , 94, 2318-2329	4.9	30
135	Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. <i>Hepatology International</i> , 2013 , 7, 443-50	8.8	8
134	Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models. 2013 , 28 Suppl 1, 120-4		15
133	Mechanism of the dependence of hepatitis B virus genotype G on co-infection with other genotypes for viral replication. <i>Journal of Viral Hepatitis</i> , 2013 , 20, e27-36	3.4	15
132	Phylogenetic analysis and subgenotypic distribution of the hepatitis B virus in Recife, Brazil. 2013 , 14, 195-9		18
131	The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. 2013 , 56, 951-60		30
130	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7671-9	5.6	6
129	Molecular epidemiology of hepatitis B in the Indigenous people of northern Australia. 2013 , 28, 1234-41		38
128	Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress. 2013 , 78, 230-7		6
127	New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. <i>Antiviral Therapy</i> , 2013 , 18, 1-15	1.6	35
126	Melting curve analysis for the screening of hepatitis B virus genotypes A, D and F in patients from a general hospital in southern Brazil. 2013 , 50, 219-25		4
125	High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon. <i>PLoS ONE</i> , 2013 , 8, e80346	3.7	32
124	Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7169-80	5.6	15

123	Potential mechanisms of hepatitis B virus induced liver injury. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12462-72	5.6	28
122	Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. 2014 , 10, e1004032		147
121	Distribution of hepatitis B virus genotypes in azerbaijani patients with chronic hepatitis B infection. <i>Hepatitis Monthly</i> , 2014 , 14, e25105	1.8	5
120	HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. 2014 , 86, 64-70		23
119	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. 2014 , 60, 1911-9		33
118	Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 925-9	3.4	9
117	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. 2014 , 29, 1005-11		15
116	Hepatitis B virus infection. 2014 , 384, 2053-63		930
115	A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon- λ variant with peginterferon- α 2a in healthy subjects. 2015 , 79, 650-9		6
114	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 526-32	13.4	38
113	Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes. 2015 , 33, 4548-53		4
112	Optimal management of hepatitis B virus infection - EASL Special Conference. <i>Journal of Hepatology</i> , 2015 , 63, 1238-53	13.4	81
111	Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. 2015 , 87, 5173-80		42
110	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. 2015 , 35, 2246-55		56
109	New paradigms in hepatitis B management: only diamonds are forever. 2015 , 116, 79-91		8
108	In vitro and in vivo replication of a chemically synthesized consensus genome of hepatitis B virus genotype B. 2015 , 213, 57-64		10
107	Hepatitis B virus (HBV) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (CHB) disease phases. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 416-26	3.4	24
106	Epidemiology of HBV subgenotypes D. 2015 , 39, 28-37		23

105	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. 2016 , 36, 1108-15			18
104	The Gamma-Glutamyl-Transpeptidase to Platelet Ratio Does not Show Advantages than APRI and Fib-4 in Diagnosing Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis B: A Retrospective Cohort Study in China. 2016 , 95, e3372			33
103	Virological characteristics of hepatitis B genotype G/A2 recombination virus in Japan. 2016 , 46, 775-83			2
102	Overview of hepatitis B viral replication and genetic variability. <i>Journal of Hepatology</i> , 2016 , 64, S4-S16	13.4		230
101	Virological and serological tools to optimize the management of patients with chronic hepatitis B. 2016 , 36 Suppl 1, 78-84			7
100	High prevalence of HBV/A1 subgenotype in native south Americans may be explained by recent economic developments in the Amazon. 2016 , 43, 354-63			2
99	In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes. 2016 , 90, 10054-10064			30
98	Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). 2016 , 30, 144-150			21
97	Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 170-9		3.4	10
96	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. 2016 , 14, 1647-1656.e6			29
95	Wild type HBx and truncated HBx: Pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms. 2016 , 26, 57-73			5
94	Global strategies are required to cure and eliminate HBV infection. 2016 , 13, 239-48			98
93	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. 2016 , 10, 177-86			7
92	The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. 2016 , 303-324			3
91	Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. 2017 , 66, 2013-2023			34
90	Ethics and hepatitis B cure research. 2017 , 66, 389-392			10
89	Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. 2017 , 37, 1116-1121			18
88	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. 2017 , 186, 356-366			7

87	Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes. 2017 , 502, 1-12		14
86	A novel hepatitis B virus subgenotype D10 circulating in Ethiopia. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 163-173	3-4	11
85	Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. 2017 , 32, 73-81		4
84	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. 2018 , 33, 503-510		16
83	Novel HBV recombinants between genotypes B and C in 3S terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. 2018 , 57, 26-35		4
82	Alpha-enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 289-295	3-4	3
81	Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. 2018 , 150, 93-100		19
80	Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. 2018 , 18, 1085-1094		13
79	Phylogenetic analysis and genotype distribution of Hepatitis B Virus (HBV) in Roraima, Brazil. 2018 , 60, e35		3
78	In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease. 2018 , 519, 190-196		15
77	Genotyping of hepatitis B virus isolates from Lahaul and Spiti district in Himachal Pradesh, India. 2018 , 37, 261-265		3
76	Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. 2018 , 48, 300-312		25
75	rt269I Type of Hepatitis B Virus (HBV) Leads to HBV e Antigen Negative Infections and Liver Disease Progression via Mitochondrial Stress Mediated Type I Interferon Production in Chronic Patients With Genotype C Infections. 2019 , 10, 1735		3
74	Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh. <i>PLoS ONE</i> , 2019 , 14, e0218744	3-7	4
73	Genotype distribution of hepatitis B virus in a subset of infected young people in Central Nigeria. 2019 , 5, e00122		0
72	Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018. <i>Scientific Reports</i> , 2019 , 9, 13948.9		11
71	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. 2019 , 39, 1624-1630		22
70	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. 2019 , 10,		11

69	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019 , 71, 456-464	13.4	91
68	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. 2019 , 17, 1850-1859.e4		26
67	Acute Hepatitis B. 2019 , 25-44		
66	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019 , 9, 2508	4.9	10
65	Molecular epidemiology of hepatitis B virus genotypes in blood donors in Islamabad, Pakistan. 2019 , 11, 240-243		1
64	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. 2019 , 10, e00036		10
63	Hepatitis B virus and hepatitis delta virus subtypes circulating in Algeria and seroprevalence of HDV infection. 2019 , 91, 72-80		2
62	Hepatitis B Virus: Asian Perspective. 2019 , 99-116		2
61	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. 2020 , 18, 693-699.e1		16
60	Molecular epidemiology, phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia: Predominance of genotype D1. 2020 , 77, 104051		3
59	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. 2020 , 5, 167-228		120
58	Analysis of the in vitro replication phenotype of African hepatitis B virus (HBV) genotypes and subgenotypes present in Australia identifies marked differences in DNA and protein expression. 2020 , 540, 97-103		2
57	A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1352-1358	3.4	3
56	Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region. <i>Frontiers in Microbiology</i> , 2020 , 11, 616023	5.7	10
55	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. 2020 , 52, 196-204		16
54	The evolution and clinical impact of hepatitis B virus genome diversity. 2020 , 17, 618-634		43
53	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. 2020 , 11, e00140		9
52	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. 2020 , 40, 1736-1743		15

51	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. 2021 , 73, 1652-1670		4
50	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 95-104	3-4	4
49	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. 2021 , 51, 406-416		2
48	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. 2021 , 84, 68-73		1
47	Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. 2021 , 27, 207-218		5
46	Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis. <i>World Journal of Hepatology</i> , 2021 , 13, 144-150	3-4	1
45	Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. <i>Scientific Reports</i> , 2021 , 11, 1365	4-9	4
44	External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 951-958	3-4	2
43	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. 2021 , 89, 48-55		6
42	Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NBVac Study). 2021 , 39, 4659-4670		1
41	Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. 2021 , 27, 402-412		6
40	Hepatitis B virus infection modeling using multi-cellular organoids derived from human induced pluripotent stem cells. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4784-4801	5-6	2
39	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1545-1553	3-4	0
38	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021 , 15, 1083-1092	8-8	5
37	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021 , 1		4
36	Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome. <i>Journal of General Virology</i> , 2018 , 99, 1103-1114 ⁸	4-9	114 ⁸
35	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 832-837	4	17
34	New perspectives on the hepatitis B virus life cycle in the human liver. <i>Journal of Clinical Investigation</i> , 2016 , 126, 833-6	15-9	11

33	Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. <i>PLoS ONE</i> , 2013 , 8, e65336	3.7	62
32	Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. <i>PLoS ONE</i> , 2015 , 10, e0118062	3.7	19
31	Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan. <i>PLoS ONE</i> , 2016 , 11, e0157103	3.7	5
30	MOLECULAR-EPIDEMIOLOGICAL FEATURES OF HEPATITIS B VIRUS. <i>Russian Journal of Infection and Immunity</i> , 2016 , 5, 297-302	0.4	1
29	Molecular and epidemiological characteristics of hepatitis B virus in conditions of mass vaccine prophylaxis. <i>MediA1</i> , 2019 , 10-39	0.5	5
28	Management of antiviral drug resistance in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11641-9	5.6	16
27	Clinical relevance of hepatitis B virus variants. <i>World Journal of Hepatology</i> , 2015 , 7, 1086-96	3.4	29
26	Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B. <i>Hepatitis Monthly</i> , 2015 , 15, e30790	1.8	3
25	Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013 , 14, 3555-9	1.7	11
24	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
23	A fatal case of acute liver failure with hepatitis B virus genotype D infection. <i>Acta Hepatologica Japonica</i> , 2013 , 54, 748-754	0.3	
22	HBV Virus in the Future. 2016 , 31-64		
21	High Risk of HBV Infection Among Vaccinated Polytransfused Children With Malignancy. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e45-e50	1.2	1
20	Biological Characterization of Hepatitis B virus Genotypes: Their Role in Viral Replication and Antigen Expression. <i>Frontiers in Microbiology</i> , 2021 , 12, 758613	5.7	0
19	Polymorphism of IFN- γ (+874 T/A) in Syrian patients with chronic hepatitis B. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2017 , 10, 34-38	1.2	4
18	Phylogenetic Analysis of Virus among Household Members with HBV Chronic Infection. <i>Avicenna Journal of Medical Biotechnology</i> , 2019 , 11, 221-228	1.4	1
17	Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
16	Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection.. <i>Scientific Reports</i> , 2022 , 12, 1651	4.9	0

- 15 In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates.. *Virologica Sinica*, **2022**, 6.4 ○
- 14 Table_1.DOCX. **2019**,
- 13 Image_1.TIF. **2020**,
- 12 Image_2.TIF. **2020**,
- 11 Image_3.TIF. **2020**,
- 10 Image_4.TIF. **2020**,
- 9 Image_5.TIF. **2020**,
- 8 Table_1.XLSX. **2020**,
- 7 Table_2.DOCX. **2020**,
- 6 Virological Treatment Monitoring for Chronic Hepatitis B. *Viruses*, **2022**, 14, 1376 6.2
- 5 Hepatitis B virus infection: Overview and new treatment targeting NTCP. **2022**,
- 4 Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analogue therapy in chronic hepatitis B patients. ○
- 3 Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg -positive chronic hepatitis B. ○
- 2 Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. ○
- 1 Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study. **2023**, Publish Ahead of Print, ○